peak_peptides_australia_ Facebook ad: “Exploring the cutting edge of metabolic science!”

About this ad

Meta Ad Library ID

4415735818647477

Platforms

Instagram

Relaunches

0

Niche

Supplements & Wellness

How we count

Ad text

Exploring the cutting edge of metabolic science! 🔬 Today, we’re looking at Retatrutide (LY3437943), an investigational compound currently in late-stage clinical development by Eli Lilly. What makes Retatrutide a point of significant scientific interest is its novel mechanism as a triple agonist. Unlike previous compounds, it is engineered to activate three distinct hormone receptors involved in metabolism and appetite regulation: 1. GLP-1 (Glucagon-like peptide-1) 2. GIP (Glucose-dependent insulinotropic polypeptide) 3. Glucagon This multi-receptor approach is a new frontier in peptide research. Phase 2 clinical trial results, published in the New England Journal of Medicine, have spurred further investigation, and large-scale Phase 3 trials are now underway to rigorously evaluate its profile in thousands of participants. The scientific community is closely watching the development of this compound as it progresses through the formal clinical trial process. It represents a fascinating evolution in the study of metabolic pathways. Disclaimer: This content is for educational and informational purposes only. Retatrutide is an investigational compound and is not approved for public use by the FDA or other regulatory agencies. It can only be administered in controlled clinical trial settings. This post does not constitute medical advice or promote the use of any unapproved substance. #Retatrutide #ClinicalTrials #DrugDevelopment #Metabolism #Endocrinology #PeptideScience #GLP1 #GIP #Glucagon #MedicalResearch #EliLilly #Investigational #ScienceNews #FutureofMedicine #NEJM

Where the ad sends people